Related Experiment Videos

Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice

Insights

Phosphonoacetic acid (PAA) resistance impacts herpes simplex virus (HSV) treatment. PAA effectively treated PAA-susceptible HSV infections, but not PAA-resistant strains in mice.

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Background:

  • Herpes simplex virus (HSV) infections are common worldwide.
  • Antiviral drugs like phosphonoacetic acid (PAA) are used to treat HSV.
  • Drug resistance can limit the efficacy of antiviral therapies.

Purpose of the Study:

  • To investigate the efficacy of PAA against PAA-resistant HSV-1.
  • To compare the effectiveness of PAA and 9-beta-d-arabinofuranosyl-adenine (ara-A) in treating HSV infections with varying PAA susceptibility.
  • To evaluate antiviral treatment strategies in a preclinical animal model.

Main Methods:

  • Isolation of a phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) population through serial passage in vitro.
  • Induction of skin infections in hairless mice using either PAA-susceptible or PAA-resistant HSV-1 strains.
  • Intraperitoneal administration of PAA and 9-beta-d-arabinofuranosyl-adenine (ara-A) using diverse dosage regimens.

Main Results:

  • 9-beta-d-arabinofuranosyl-adenine (ara-A) demonstrated efficacy against both PAA-susceptible and PAA-resistant HSV-1 skin infections.
  • Phosphonoacetic acid (PAA) effectively suppressed infections caused by the parental PAA-susceptible HSV-1 strain.
  • PAA failed to suppress infections caused by the isolated PAA-resistant HSV-1 population.

Conclusions:

  • Development of PAA resistance in HSV-1 compromises the therapeutic effectiveness of PAA.
  • Alternative antiviral agents like ara-A may retain efficacy against drug-resistant HSV strains.
  • This study highlights the importance of monitoring antiviral resistance in HSV treatment strategies.

Related Concept Videos